



CONTACT | Media:

+31.20.550.4098 (Amsterdam), +32.2.509.1392 (Brussels)

+351.217.900.029 (Lisbon), +44.20.7379.2789 (London)

+1.212.656.2411 (New York), +33.1.49.27.11.33 (Paris)

CONTACT | Investor Relations:

+1.212.656.5700 (New York)

+33.1.49.27.58.60 (Paris)

NYSE Euronext's Alternext Welcomes Ipsogen - Seventh listing and second IPO on Alternext this year -

Paris, June 10, 2008 – NYSE Euronext (NYX) today announced the IPO and listing of Ipsogen, a pioneering biotechnology company specializing in the development and marketing of molecular diagnostic tests for cancer, on its Alternext Paris market.

Ipsogen began trading on Alternext Paris under the ticker symbol “ALIPS”. A total of 1,634,718 new shares were subscribed, raising a total of €1.8 million. At the IPO price of €7.20, the market capitalization of the company amounts to €31.9 million.

“We are delighted to welcome Ipsogen to Alternext, the second Public Offer and the seventh listing this year. We look forward to a beneficial and lasting partnership with Ipsogen and to providing the company with the highest levels of service, liquidity and brand visibility associated with listing on NYSE Euronext markets” said Martine Charbonnier, Head of European Listings at NYSE Euronext.

Vincent Fert, CEO of Ipsogen, declared: “Ipsogen is excited to become part of the NYSE Euronext community of listed companies. The successful IPO despite adverse market conditions underlines Ipsogen's potential in personalized medicine.”

Ipsogen will be included in NYSE Euronext's new Bio-tech Index, “Next Biotech” which now comprises 26 biotech companies listed on NYSE Euronext's European markets and enables investors to track the performance of the fast-growing and innovative Biotech sector at a European level.

Ipsogen is the seventh company to list on Alternext, NYSE Euronext's specialist market for small and mid-sized companies, this year and follows three international companies. Ipsogen is also the first biotech company to list on NYSE Euronext's European markets since the beginning of the year.

Alternext, launched in 2005, now includes 125 listed companies, including companies from Belgium, Canada, China, France, Italy, Luxembourg, the Netherlands, Spain and the UK. Together, they have raised €1.6 billion and their total market capitalization stands at €5.6 billion.

Notes to Editors:

About Ipsogen

Ipsogen, based in Marseille, France and New Haven, USA, is a pioneering biotechnology company utilizing advanced technologies to analyse gene expression and to improve the disease management of cancers.

About NYSE Euronext

NYSE Euronext (NYX) operates the world's leading and most liquid exchange group, and seeks to provide the highest levels of quality, customer choice and innovation. Its family of exchanges, located in six countries, includes the New York Stock Exchange, the world's largest cash equities market; Euronext, the Eurozone's largest cash equities market; Liffe, Europe's leading derivatives exchange by value of trading; and NYSE Arca Options, one of the fastest growing U.S. options trading platforms. NYSE Euronext offers a diverse array of financial products and services for issuers, investors and financial institutions in cash equities, options and derivatives, ETFs, bonds, market data, and commercial technology solutions. NYSE Euronext's nearly 4,000 listed companies represent a combined \$ 30.9/ €19.8 trillion in total global market capitalization (as of April 30, 2008), more than four times that of any other exchange group. NYSE Euronext's equity exchanges transact an average daily trading value of approximately \$161.9 / €106.9 billion (as of April 30, 2008), which represents more than one-third of the world's cash equities trading. NYSE Euronext is part of the S&P 500 index and the only exchange operator in the S&P 100 index. For more information, please visit www.nyx.com.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning NYSE Euronext's plans, objectives, expectations and intentions and other statements that are not historical or current facts. Forward-looking statements are based on NYSE Euronext's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause NYSE Euronext's results to differ materially from current expectations include, but are not limited to: NYSE Euronext's ability to implement its strategic initiatives, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk and U.S. and global competition, and other factors detailed in NYSE Euronext's reference document for 2007 ("document de référence") filed with the French Autorité des Marchés Financiers (Registered on May 15, 2008 under No. R. 08-054), 2007 Annual Report on Form 10-K and other periodic reports filed with the U.S. Securities and Exchange Commission or the French Autorité des Marchés Financiers. In addition, these statements are based on a number of assumptions that are subject to change. Accordingly, actual results may be materially higher or lower than those projected. The inclusion of such projections herein should not be regarded as a representation by NYSE Euronext that the projections will prove to be correct. This press release speaks only as of this date. NYSE Euronext disclaims any duty to update the information herein.